Phase 1 Study on Bioavailability, Food Effect, and Safety of INF904 Capsule Formulations in Healthy Volunteers

The primary objective of this study is to evaluate the **bioavailability** of capsule formulations of INF904 in healthy volunteers. This assessment is crucial for determining the extent and rate at which the active ingredient is absorbed and becomes available at the site of action, which is essential for understanding the drug's pharmacokinetic profile and ensuring its therapeutic efficacy. Additionally, the study aims to investigate the effect of food on the bioavailability of these formulations, providing valuable insights into potential dietary considerations for optimal drug administration. The study also focuses on assessing the safety profile of the capsule formulations, which is vital for identifying any adverse effects and ensuring the well-being of participants during the trial.

The clinical trial involves **healthy volunteers** with an age range of 18 to 65 years, including both male and female participants. The sponsor has not provided the total number of participants. The trial population was selected to include a vulnerable population, although specific details regarding selection criteria or lifestyle considerations such as diet, physical activity, or habits have not been disclosed. The study does not focus on any specific medical condition, as it involves healthy individuals. Key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed as a **Phase 1**, randomized, open-label, single-dose crossover study. The primary aim is to assess the relative bioavailability, food effect, and safety of capsule formulations of INF904 in healthy volunteers. The trial is scheduled to commence recruitment on June 15, 2024, and is expected to conclude by April 16, 2025. Participants will be involved in the study for a duration that aligns with the trial's timeline, with specific involvement periods determined by the study protocol.

The trial will begin with an inclusion visit, where potential participants will undergo a screening process to ensure they meet the eligibility criteria. This visit will include assessments to confirm the health status of the volunteers, as the study is conducted with healthy individuals. Following successful screening, participants will be randomized to receive the study drug under different conditions to evaluate the bioavailability and food effect. The open-label design means that both the participants and the investigators will be aware of the treatment being administered.

Throughout the study, participants will attend follow-up visits as outlined in the study protocol. These visits are crucial for monitoring the safety and efficacy of the drug, as well as for collecting data on pharmacokinetics and any potential adverse effects. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to ensure the well-being of the participants and to gather comprehensive data for analysis.

Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study procedures, or withdraw consent. The study's design and procedures are structured to ensure the safety of participants while providing valuable data on the investigational drug's properties.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these treatments cannot be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the data. As such, these details cannot be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on June 15, 2024, with an estimated completion date of April 16, 2025. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger patient population. The trial's design and execution will be aligned with regulatory requirements to ensure the reliability and validity of the efficacy outcomes.